BioCryst adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to its HAE portfolio. The potential to be the first HAE therapy with ...

After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...

IONS secures EU approval for Dawnzera in hereditary angioedema, after FDA clearance in the United States in August last year.

Hereditary angioedema (HAE) is a rare genetic condition that causes swelling under the skin and lining of your gut and lungs. “Angio” means it affects your blood vessels. “Edema” means swelling. So ...

Deficiency of functional C1-INH activity is an autosomal dominant genetic disorder that can be further classified into 2 types. Type I HAE, which accounts for approximately 85% of cases, occurs due to ...

Ionis Pharma & Otsuka’s donidalorsen gets approval in European Union for hereditary angioedema: Carlsbad, California Saturday, January 24, 2026, 13:00 Hrs [IST] Ionis Pharmaceut ...

Otsuka’s Dawnzera is now approved in the EU to prevent hereditary angioedema attacks in patients 12 and older, offering a ...

Please provide your email address to receive an email when new articles are posted on . The patient, aged 66 years, had no previous edema. The patient tested positive for a mutation in the plasminogen ...

Ionis Pharmaceuticals (IONS) and its Japanese partner, Otsuka Pharmaceutical (OTSKY), said on Wednesday that the European ...

Hereditary angioedema is a potentially life-threatening autosomal dominant condition, causing attacks of angioedema due to failure to regulate bradykinin. Nearly all cases of hereditary angioedema are ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) ...